Literature DB >> 10094949

Cost analysis for the prevention of variceal rebleeding: a comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients.

P Meddi1, M Merli, R Lionetti, A De Santis, V Valeriano, A Masini, P Rossi, F Salvatori, F Salerno, R de Franchis, L Capocaccia, O Riggio.   

Abstract

The aim of the present study was to compare the cumulative cost of the first 18-month period in a selected group of Italian cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic sclerotherapy (ES) to prevent variceal rebleeding. Thirty-eight patients enrolled in a controlled trial were considered (18 TIPS and 20 sclerotherapy). The number of days spent in the hospital for the initial treatment and during the follow-up period were defined as the costs of hospitalization. ES sessions, TIPS procedures, angioplasty or addition of a second stent to maintain the shunt patency, were defined as the costs of therapeutic procedures. The two groups were comparable for age, sex, and Child-Pugh score. During the observation period 4 patients died in the TIPS group, and 2 died and 1 was transplanted in the sclerotherapy group. The rebleeding rate was significantly higher in the sclerotherapy group. Despite this, the number of days spent in the hospital was similar in the two groups. This was because of a higher number of hospital admissions for the treatment of hepatic encephalopathy and shunt insufficiency in the TIPS group. The therapeutic procedures were more expensive for TIPS. Consequently, the cumulative cost was higher for patients treated with TIPS than for those treated with sclerotherapy. The extra cost was because of the initial higher cost of the procedure and the difference was still maintained at the end of the 18-month follow-up. When the cumulative costs were expressed per month free of rebleeding, the disadvantage of TIPS disappeared. In conclusion, a program of prevention of variceal rebleeding with TIPS, despite the longer interval free of rebleeding, is not a cost-saving strategy in comparison with sclerotherapy.

Entities:  

Mesh:

Year:  1999        PMID: 10094949     DOI: 10.1002/hep.510290411

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.

Authors:  G Pomier-Layrargues; J P Villeneuve; M Deschênes; B Bui; P Perreault; D Fenyves; B Willems; D Marleau; M Bilodeau; M Lafortune; M P Dufresne
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

2.  Should stent-grafts replace bare stents for primary transjugular intrahepatic portosystemic shunts?

Authors:  Manfred Cejna
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 3.  Current management of portal hypertension.

Authors:  Andrew S Wright; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

Review 4.  Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis.

Authors:  S Khan; C Tudur Smith; P Williamson; R Sutton
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt.

Authors:  Thomas D Boyer; J Michael Henderson; Adrienne M Heerey; Susana Arrigain; Vicky Konig; Jason Connor; Kareem Abu-Elmagd; John Galloway; Layton F Rikkers; Lennox Jeffers
Journal:  J Hepatol       Date:  2007-10-23       Impact factor: 25.083

6.  Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Danielle Roberts; Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Sivapatham Arunan; Tanjia Begum; Norman R Williams; Dana Walshaw; Elisabeth Jane Milne; Maxine Tapp; Mario Csenar; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-10

7.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

8.  Combination therapy versus pharmacotherapy, endoscopic variceal ligation, or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized controlled trials.

Authors:  Lu-Lu Lin; Shi-Ming Du; Yan Fu; Hui-Yun Gu; Lei Wang; Zhi-Yuan Jian; Xian-Feng Shen; Jie Luo; Chao Zhang
Journal:  Oncotarget       Date:  2017-05-24

9.  Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.

Authors:  Rosa G Simonetti; Giovanni Perricone; Helen L Robbins; Narendra R Battula; Martin O Weickert; Robert Sutton; Saboor Khan
Journal:  Cochrane Database Syst Rev       Date:  2020-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.